Redefining the Scholar-Athlete: China Biotech CEOs


NetEase | July 21, 2020

​ ​

The NetEase article, “Redefining the Scholar-Athlete: China Biotech CEOs," featured Russell Reynolds Associates' insight report, created in partnership with BayHelix Group, on key competencies for China biotech CEOs. The article is excepted below.

China's nascent biotech industry is booming. To better understand China's leading bi​​otech CEOs, BayHelix Group and Russell Reynolds Associates had conversations with selected biotech CEOs and investors who shared their most critical challenges and considerations.

This research, along with Russell Reynolds Associates' deep market knowledge, helps illuminate the leadership profiles that have built China's biotech sector to date, and which qualities and experiences will be most essential for the market's continued development and success.

  • ​Close to 80 percent of current CEOs are company founders, nearly 75 percent of current CEOs have PhDs

  • With most coming from R&D backgrounds, these CEOs have deep scientific experience as well as a profound understanding of the China biotech landscape, average tenure is 9.5 years

  • 42 percent of the current biotech CEOs worked for large pharma companies; 66 percent were previously in biotech

To read the full article, click here​

This article has also been featured in the news sites shown below.


Sign up for our newsletter

Get the newsletter that prepares you for what's next with valuable insights across industries and geographies.
Redefining the Scholar-Athlete: China Biotech CEOs